Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Q2 2020 Earnings Conference Call - Final Transcript

Jul 30, 2020 • 04:30 pm ET

Previous

Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Q2 2020 Earnings Conference Call - Final Transcript

Share
Close

Loading Event

Loading Transcript

Q & A
Executive
Jayson Dallas

And so therefore, inventory is held at our specialty pharmacy level. We recognize revenue when drugs -- when product changes hands from the 3PL to the specialty pharmacy.

So -- and then, Eric, you want to just add a bit more to that and answer Derek's second question?

Executive
Eric Bjerkholt

Yes. In terms of the runway, which is the essence of your question, we do see ourselves as fully funded based on our current business plan. And our current business plan, of course, makes assumptions about how we see the introduction of PALFORZIA continuing to ramp. So we feel good about that.

And then in terms of the burn rate, yes, I mean, it should be -- we continue to manage our expenses very closely. And every quarter, there's some give and takes up and down, but we can continue to see really good cost -- we expect to see continued really good cost containment for the rest of the year.

Analyst
Derek Archila

All right. Thanks, guys.

Operator
Operator

Thank you. And I'm showing no further questions at this time. And I would like to turn the conference back over to Jayson Dallas for any further remarks.

Executive
Jayson Dallas

Thank you, everyone, for joining our call today. I'm very proud of the team at Aimmune and the progress that we've made during this extremely challenging time. With almost 1,000 physicians signed up for the REMS, payer policies covering 102 million lives and our recently initiated targeted consumer marketing campaigns, we anticipate the PALFORZIA launch picking up over the coming months. Our market research shows that there is still strong demand from allergists and caregivers for a treatment for peanut allergy, and we're excited to be able to offer them the first and only FDA-approved therapy. We have been and will continue to be thoughtful about our spend so that we can get PALFORZIA to those in need while preserving capital. We believe the long-term prospects for PALFORZIA and Aimmune remains strong and promising, and we look forward to providing future updates.

As always, I thank you for your ongoing support and for joining us on today's call.

Operator
Operator

[Operator Closing Remarks]